Trudo Lemmens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6760516/publications.pdf

Version: 2024-02-01

52 papers	1,700 citations	430874 18 h-index	302126 39 g-index
54 all docs	54 docs citations	54 times ranked	1439 citing authors

#	Article	IF	Citations
1	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. BMJ Global Health, 2022, 7, e008684.	4.7	122
2	Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. International Journal of Health Services, 2021, 51, 5-13.	2.5	11
3	Regulation of health professions in Ontario: self-regulation with statutory- based public accountability. Revista De Direito Sanitario, 2019, 19, 124-204.	0.1	2
4	When a Theoretical Commitment to Broad Physician Aid-in-Dying Faces the Reality of Its Implementation. American Journal of Bioethics, 2019, 19, 65-68.	0.9	5
5	Clinical trial transparency in the Americas: the need to coordinate regulatory spheres. BMJ: British Medical Journal, 2018, 362, k2493.	2.3	3
6	The institutional workers of biomedical science: Legitimizing academic entrepreneurship and obscuring conflicts of interest. Science and Public Policy, 2018, 45, 404-415.	2.4	5
7	Transparency of Biobank Access in Canada: An Assessment of Industry Access and the Availability of Information on Access Policies and Resulting Research. Journal of Empirical Research on Human Research Ethics, 2017, 12, 310-325.	1.3	6
8	Should assisted dying for psychiatric disorders be legalized in Canada?. Cmaj, 2016, 188, E337-E339.	2.0	63
9	Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine. World Medical and Health Policy, 2015, 7, 3-27.	1.6	8
10	How Can Journals Respond to Threats of Libel Litigation?. PLoS Medicine, 2014, 11, e1001615.	8.4	3
11	Niche Markets and Evidence Assessment in Transition: A Critical Review of Proposed Drug Reforms. Medical Law Review, 2014, 22, 200-220.	0.5	14
12	Investigating Research and Accessing Reproductive Material. Journal of Bioethical Inquiry, 2014, 11, 11-19.	1.5	1
13	Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles. Medical Writing, 2013, 22, 264-271.	0.1	0
14	The OHRP and SUPPORT â€" Another View. New England Journal of Medicine, 2013, 369, e3.	27.0	53
15	Pharmaceutical Knowledge Governance: A Human Rights Perspective. Journal of Law, Medicine and Ethics, 2013, 41, 163-184.	0.9	24
16	Global Health Challenges and the Role of Law. Journal of Law, Medicine and Ethics, 2013, 41, 9-15.	0.9	4
17	Access to information and the right to health: the human rights case for clinical trials transparency. American Journal of Law and Medicine, 2012, 38, 63-112.	0.2	12
18	Legal Remedies for Medical Ghostwriting: Imposing Fraud Liability on Guest Authors of Ghostwritten Articles. PLoS Medicine, 2011, 8, e1001070.	8.4	52

#	Article	IF	Citations
19	Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2011, 30, 87-96.	1.1	9
20	Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network. Open Medicine, 2010, 4, e123-8.	1.5	1
21	7th Revision of the Declaration of Helsinki: Good News for the Transparency of Clinical Trials. Croatian Medical Journal, 2009, 50, 105-110.	0.7	114
22	Does the FDA have the authority to trump the Declaration of Helsinki?. BMJ: British Medical Journal, 2009, 338, b1559-b1559.	2.3	16
23	Privatizing biomedical researchâ€"a 'third way'. Nature Biotechnology, 2008, 26, 31-36.	17.5	22
24	Research Ethics Recommendations for Whole-Genome Research: Consensus Statement. PLoS Biology, 2008, 6, e73.	5.6	212
25	Financial conflict of interest in medical research. , 2008, , 222-230.		4
26	The Declaration of Helsinki. BMJ: British Medical Journal, 2007, 335, 624-625.	2.3	401
27	Should Society Allow Research Ethics Boards to Be Run As For-Profit Enterprises?. PLoS Medicine, 2006, 3, e309.	8.4	29
28	The social and cultural shaping of medical evidence: Case studies from pharmaceutical research and obstetric science. Social Science and Medicine, 2006, 62, 2694-2706.	3.8	66
29	Research Ethics Boards: Reply from Trudo Lemmens and Carl Elliott. PLoS Medicine, 2006, 3, e471.	8.4	2
30	Regulating the Market in Human Research Participants. PLoS Medicine, 2006, 3, e330.	8.4	6
31	Federal regulation of REB review of clinical trials: a modest but easy step towards an accountable REB review structure in Canada. Health Law Review, 2005, 13, 39-50.	0.1	8
32	Integrating Values in Risk Analysis of Biomedical Research: The Case for Regulatory and Law Reform. University of Toronto Law Journal, 2004, 54, 249-290.	0.2	5
33	CIOMS' Placebo Rule and the Promotion of Negligent Medical Practice. European Journal of Health Law, 2004, 11, 153-174.	0.2	3
34	Currents in Contemporary Ethics. Journal of Law, Medicine and Ethics, 2004, 32, 365-368.	0.9	2
35	Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene. Journal of Law, Medicine and Ethics, 2004, 32, 641-657.	0.9	38
36	Piercing the Veil of Corporate Secrecy about Clinical Trials. Hastings Center Report, 2004, 34, 14.	1.0	8

#	Article	IF	Citations
37	Confronting the conflict of interest crisis in medical research. Monash Bioethics Review, 2004, 23, 19-40.	0.8	7
38	The Human Subjects Trade: Ethical and Legal Issues Surrounding Recruitment Incentives. Journal of Law, Medicine and Ethics, 2003, 31, 398-418.	0.9	33
39	Avoiding a Jekyll-And-Hyde Approach to the Ethics of Clinical Research and Practice. American Journal of Bioethics, 2002, 2, 14-17.	0.9	30
40	Noninstitutional Commercial Review Boards in North America. IRB: Ethics & Human Research, 2001, 23, 1.	0.8	9
41	Justice for the Professional Guinea Pig. American Journal of Bioethics, 2001, 1, 51-53.	0.9	67
42	Ethics Review for Sale? Conflict of Interest and Commercial Research Review Boards. Milbank Quarterly, 2000, 78, 547-584.	4.4	80
43	Title is missing!. European Journal of Health Law, 2000, 7, 265-292.	0.2	7
44	Private Parties, Public Duties?. , 1999, , 31-39.		2
45	In the Name of National Security: Lessons from the Final Report on the Human Radiation Experiments. European Journal of Health Law, 1999, 6, 7-23.	0.2	1
46	Guinea Pigs on the payroll: The ethics of paying research subjects. Accountability in Research, 1999, 7, 3-20.	2.4	79
47	Conflict of Interest and Commercialization of Biomedical Research. , 1999, , 79-99.		2
48	Structuring the Review of Human Genetics Protocols Part II: Diagnostic and Screening Studies. IRB: Ethics & Human Research, 1997, 19, 1.	0.8	25
49	â€œWhat About Your Genes?â€•Ethical, Legal, and Policy Dimensions of Genetics in the Workplace. Politics and the Life Sciences, 1997, 16, 57-75.	0.7	10
50	Towards the right to be killed?: Treatment refusal, assisted suicide and euthanasia in the United States and Canada. British Medical Bulletin, 1996, 52, 341-353.	6.9	7
51	Euthanasia and the Good Life. Perspectives in Biology and Medicine, 1995, 39, 15-27.	0.5	1
52	Decreasing the Data Deficit: Improving Post-Market Surveillance in Pharmaceutical Regulation. McGill Law Journal, 0, 59, 943-988.	0.1	5